Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters;Aplicación de modelos estructurales marginales para estimar los efectos de la terapia antirretroviral en 5 cohortes de seroconvertores al virus de la inmunodeficiencia humana

Gaceta Sanitaria

Volumn 21, Issue 1, 2007, Pages 76-83

  Pérez Hoyos, Santiago ^a,b   Ferreros, Inmaculada ^a,c,e   Hernán, Miguel A ^d   del Amo, Julia ^c   Hernández Aguado, Ildefonso ^c   Muga, Robert ^f   Sanvicens, Arantza ^f   Clotet, Bonaventura ^f   Tor, Jordi ^f   del Romero, Jorge ^g   Raposo, Paloma ^g   Rodríguez, Carmen ^g   García, Soledad ^g   Soriano, V Vicente ^g   Hurtado, Isabel ^h   García de la Hera, Manoli ^h   Alastrúe, Ignacio ^h   Belda, Josefina ^h   Trullen, Joseph ^h   Fernández, Elisa ^h   Santos, Concha ^h   Tasa, Teresa ^h   García de Olalla, Patricia ⁱ   Caylà, Joan A ⁱ   el Guerrero, Rafael ^g   Marco, Andrés ^g   Quintana, Manolo ^j   González, Cristina ^j   Ruisz, Isabel ^k   Perez, Rosario ^l   Castilla, Jesús ^m   more..

^a Generalitat Valenciana   (Spain)

^b UNIVERSITY OF ALICANTE   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d HARVARD UNIVERSITY   (United States)

^e Escuela Valenciana de Estudios para la Salud   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g CIPS de la Comunidad Valenciana ^*

^h CIPS de la Comunidad Valenciana   (Spain)

ⁱ IMSP   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^m Intituto de Salud Pública de Navarra   (Spain)

more..

Author keywords

AIDS; Marginal structural models; Survival analysis; Treatment efficacy

Indexed keywords

EID: 34047109685     PISSN: 02139111     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0213-9111(07)71974-x     Document Type: Article

References (21)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33.
2. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351: 543-9.
3. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497-503.
4. Pérez-Hoyos S, Del Amo J, Muga R, Del Romero J, García O, Guerrero R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: diferences by transmission category. AIDS. 2003;17: 353-9.
5. Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker SA, et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol. 2002;31: 951-8.
6. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267-74.
7. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70.
8. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-60.
9. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003; 158: 687-94.
10. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-84.
11. GEMES (Grupo Español Multicéntrico para el Estudio de Seroconversores). El período de incubación del sida en España antes de la terapia antirretroviral de alta eficacia. Med Clin (Barc). 2000;115:681-6.
12. Neyman J. On the application of probability theory to agricultural experiments: essay on principles, section 9. Statistical Science. 1990;5:465-80.
13. Hernan MA. A definition of causal effect for epidemiological research. J Epidemiol Community Health. 2004;58:265-71.
14. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite population. JASA. 1952;47: 663-85.
15. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol. Community Health. 2006;60: 578-86.
16. Hernan MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-25.
17. Robins JM. Marginal structural models. Proceedings or the American Statistical Association, Section on Bayesian Statistical Science, p. 1-10. Alexandria: American Statistical Association; 1998.
18. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate of joint causal effect of non-randomized treatments. JASA. 2001;96:440-8.
19. Fewell Z, Hernan MA, Wolfe F, Tilling K, Choi H, Sterne JA. Controlling for time-dependent confounding using marginal structural models. Stata J. 2004;4:402-20.
20. Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol. 2002;31:163-5.
21. Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol. 2000;152:923-33.